<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00566384</url>
  </required_header>
  <id_info>
    <org_study_id>91692</org_study_id>
    <secondary_id>310741</secondary_id>
    <secondary_id>2006-004397-27</secondary_id>
    <nct_id>NCT00566384</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Oral Dehydroepiandrosterone as a Concomitant Therapy to Oral Contraceptives in Women Complaining of Reduced Libido</brief_title>
  <official_title>Multi-center, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Daily Oral 100 mg Dehydroepiandrosterone (DHEA) Over 6 Treatment Cycles as a Concomitant Therapy to Oral Contraceptives (OC) to Alleviate Complaints of Reduced Libido in Women With Acquired Female Sexual Dysfunction (FSD) Associated With OC-use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the effectiveness of the study drug on the libido&#xD;
      (sexual desire) of women who are taking oral contraceptives and who have experienced libido&#xD;
      reductions as a side-effect of this contraceptive method The hypothesis is that there is&#xD;
      superiority in the change in sexual desire and arousal component scores of the FSFI&#xD;
      questionnaire from baseline to cycle 6 of the treatment with the study drug as compared to&#xD;
      Placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FSDS questionnaire (sexual desire and arousal component scores)</measure>
    <time_frame>at baseline and after Cycle 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline period to cycle 6 in the number of satisfactory sexual events</measure>
    <time_frame>after Cycle 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FSFI questionnaire (absolute values and change from baseline) - All domains</measure>
    <time_frame>Cycle 1, 3, 6 and follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FSDS-R questionnaire results</measure>
    <time_frame>Cycle 1, 3, 6 and follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FSEP questionnaire results</measure>
    <time_frame>Cycle 1, 3, 6 and follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PGWBI questionnaire results</measure>
    <time_frame>Cycle 1, 3, 6 and follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum hormone levels (SHBG, T, DHEA, DHEA-S)</measure>
    <time_frame>Cycle 1, 3, 6 and follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaginal pH</measure>
    <time_frame>Cycle 1, 3, 6 and follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Libido</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dehydroepiandrosterone, BAY86-5314</intervention_name>
    <description>Treatment with daily oral intake of two capsules containing 50 mg DHEA each. Treatment duration will be 24 weeks</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Treatment with daily oral intake of two capsules containing Placebo. Treatment duration will be 24 weeks</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Treatment with a oral contraceptive (OC) for at least 3 months and willing to continue&#xD;
             the OC&#xD;
&#xD;
          -  Loss of libido&#xD;
&#xD;
          -  Sexual relationship with a sexually competent partner&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female sexual dysfunction other than HSDD, arousal and orgasmic disorder, such as&#xD;
             sexual aversion/phobic disorder, sexual pain disorder/dyspareunia&#xD;
&#xD;
          -  Hyperandrogenemic conditions, such as congenital adrenal hyperplasia (CAH), polycystic&#xD;
             ovary syndrome (PCOS), Cushing's syndrome or signs of hyperandrogenism like severe&#xD;
             hirsutism or severe acne&#xD;
&#xD;
          -  Presence or a history of venous or arterial thrombotic/thromboembolic events (e.g.,&#xD;
             deep venous thrombosis, pulmonary embolism, myocardial infarction) or of a&#xD;
             cerebrovascular accident.&#xD;
&#xD;
          -  Presence or history of prodromi of a thrombosis (e.g., transient ischaemic attack,&#xD;
             angina pectoris).&#xD;
&#xD;
          -  History of migraine with focal neurological symptoms.&#xD;
&#xD;
          -  Diabetes mellitus with vascular involvement.&#xD;
&#xD;
          -  Presence of a severe or multiple risk factor(s) for venous or arterial thrombosis&#xD;
&#xD;
          -  Pancreatitis or a history thereof if associated with severe hypertriglyceridemia&#xD;
&#xD;
          -  Presence or history of severe hepatic disease as long as liver function values have&#xD;
             not returned to normal.&#xD;
&#xD;
          -  Presence or history of liver tumors (benign or malignant).&#xD;
&#xD;
          -  Known or suspected sex-steroid influenced malignancies (e.g., of the genital organs or&#xD;
             the breasts)&#xD;
&#xD;
          -  Undiagnosed vaginal bleeding.&#xD;
&#xD;
          -  Known or suspected pregnancy.&#xD;
&#xD;
          -  Hypersensitivity to the active substances or to any of the excipients.&#xD;
&#xD;
          -  Body-mass index (BMI ) more than 30.0 kg/mÂ²&#xD;
&#xD;
          -  Hypersensitivity to any of the study drug ingredients&#xD;
&#xD;
          -  Any disease or condition that can compromise the function of the body systems and&#xD;
             could result in altered absorption, excessive accumulation, impaired metabolism, or&#xD;
             altered excretion of the study medication&#xD;
&#xD;
          -  Known current or history of alcohol or drug abuse&#xD;
&#xD;
          -  Prohibited concomitant medication:&#xD;
&#xD;
               -  Use of additional steroid hormones, anticoagulants (e.g., heparin, coumarin),&#xD;
                  antiepileptics (hydantoin derivates, e.g., phenytoin or carboxamide derivates,&#xD;
                  e.g., carbamazepin, oxcarbamazepin), other antiepileptics, (e.g., Felbamate,&#xD;
                  Topiramate), hypnotic and sedative (e.g., barbiturate derivates, primidone),&#xD;
                  tuberculostatics (e.g., rifampicin), oral antimycotics (e.g., griseofulvin,&#xD;
                  ketoconazole, itraconazole, fluconazol), virostatic agents (e.g., ritonavir), and&#xD;
                  products containing St. John's wort and continuous systemic use of antibiotics.&#xD;
&#xD;
               -  Medication with influence on libido (e.g., antihypertensives like beta-adrenergic&#xD;
                  blocker, cholinesterase blocking agents), psychotropic drugs (e.g.,&#xD;
                  antidepressants, neuroleptic agents, selective serotonin reuptake inhibitors&#xD;
                  [SSRIs]), lipid lowering drugs and H2 blockers.&#xD;
&#xD;
          -  Intake of an experimental drug within 3 months prior to inclusion in the study&#xD;
&#xD;
          -  Previous assignment to treatment (e.g., randomization) during this study&#xD;
&#xD;
          -  Close affiliation with the investigational site; e.g., a close relative of the&#xD;
             investigator, dependent person (e.g., employee or student of the investigational&#xD;
             site).&#xD;
&#xD;
          -  Operation scheduled in the study period&#xD;
&#xD;
          -  Abnormal laboratory values within the non-inclusion range&#xD;
&#xD;
          -  Patient is in custody by order of an authority or a court of law&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>10115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>10247</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>10627</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>10629</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>10709</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>12435</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>13086</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>13357</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>14195</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <zip>22143</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrialsregister.eu</url>
    <description>Click here and search for Bayer products information provided by the EMA</description>
  </link>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>November 29, 2007</study_first_submitted>
  <study_first_submitted_qc>November 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2007</study_first_posted>
  <last_update_submitted>November 30, 2014</last_update_submitted>
  <last_update_submitted_qc>November 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Loss of libido</keyword>
  <keyword>Acquired, oral contraceptive -associated female sexual dysfunction</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dehydroepiandrosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

